Across TCGA pan-cancer cohorts, FAM153DP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM153DP data layer compared with 7 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher FAM153DP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM153DP expression acts as an unfavorable survival marker.
CESC are the cancer types where FAM153DP Mutation most reproducibly stratifies survival.